Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis: Dimdazenil for Insomnia.
Saved in:
| Title: | Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis: Dimdazenil for Insomnia. |
|---|---|
| Authors: | Ran, Shan (AUTHOR), Liu, Shouhuan (AUTHOR), Yan, Kewen (AUTHOR), Li, Xueyi (AUTHOR), Wu, Min (AUTHOR), Peng, Hanrui (AUTHOR), Liu, Tieqiao (AUTHOR), Li, Zejun (AUTHOR) |
| Source: | Neurological Sciences. Mar2025, Vol. 46 Issue 3, p1179-1190. 12p. |
| Subjects: | Sleep latency, Sleep duration, Sleep, Drug residues, Sleep disorders |
| Abstract: | Background: Insomnia is a common sleep disorder affecting approximately 10-20% of adults worldwide. Despite various available treatment modalities, significant gaps remain in improving sleep maintenance and reducing functional impairments. Objective: To systematically review and synthesize studies on the efficacy and safety of Dimdazenil for the treatment of insomnia. Methods: A comprehensive search of multiple databases and websites was conducted to identify published and unpublished trials from inception to July 19, 2024. Due to the limited number of studies available, quantitative data were synthesized narratively. Results: This synthesis included four randomized controlled trials. The primary efficacy endpoints of these studies met the predetermined criteria for superiority. Dimdazenil significantly improved certain objective and subjective sleep measures in patients with insomnia, including reduced sleep latency and longer total sleep duration. Importantly, these outcomes were achieved without causing significant excessive daytime drowsiness or impairing daytime functionality. Furthermore, Dimdazenil demonstrated a generally acceptable safety profile and was well tolerated. Most evaluation indicators related to withdrawal symptoms, drug residues, and rebound effects did not show significant statistical differences. Limitations: The number of included studies and sample sizes were small, and there is a lack of data on the long-term efficacy and safety of Dimdazenil. Conclusions: Dimdazenil offers significant benefits in improving sleep onset and maintenance in patients with insomnia. It presents a favorable safety and tolerability profile while preserving daytime functioning. Future studies should extend the duration and scale to assess the long-term efficacy and safety of Dimdazenil across diverse populations. [ABSTRACT FROM AUTHOR] |
| Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Insomnia is a common sleep disorder affecting approximately 10-20% of adults worldwide. Despite various available treatment modalities, significant gaps remain in improving sleep maintenance and reducing functional impairments. Objective: To systematically review and synthesize studies on the efficacy and safety of Dimdazenil for the treatment of insomnia. Methods: A comprehensive search of multiple databases and websites was conducted to identify published and unpublished trials from inception to July 19, 2024. Due to the limited number of studies available, quantitative data were synthesized narratively. Results: This synthesis included four randomized controlled trials. The primary efficacy endpoints of these studies met the predetermined criteria for superiority. Dimdazenil significantly improved certain objective and subjective sleep measures in patients with insomnia, including reduced sleep latency and longer total sleep duration. Importantly, these outcomes were achieved without causing significant excessive daytime drowsiness or impairing daytime functionality. Furthermore, Dimdazenil demonstrated a generally acceptable safety profile and was well tolerated. Most evaluation indicators related to withdrawal symptoms, drug residues, and rebound effects did not show significant statistical differences. Limitations: The number of included studies and sample sizes were small, and there is a lack of data on the long-term efficacy and safety of Dimdazenil. Conclusions: Dimdazenil offers significant benefits in improving sleep onset and maintenance in patients with insomnia. It presents a favorable safety and tolerability profile while preserving daytime functioning. Future studies should extend the duration and scale to assess the long-term efficacy and safety of Dimdazenil across diverse populations. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 15901874 |
| DOI: | 10.1007/s10072-024-07872-3 |
